Learn everything you need to know about Degarelix-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Patient undergoing cardiovascular check-up. The risk of death from any cause was higher with degarelix. Degarelix did not reduce the risk of major adverse cardiovascular events (MACE) when compared ...

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...

ORLANDO -- PSA progression slowed significantly in prostate cancer patients switched to degarelix (Firmagon) after 12 months of leuprolide therapy, data from an open-label extension study showed. The ...

ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...

On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...

Survey on management of metastatic hormone-refractory prostate cancer upon progression during or following first-line chemotherapy in five European countries. a Mean IPSS at baseline was relatively ...

Degarelix approved for advanced prostate cancer Degarelix (from Ferring Pharmaceutical), an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, is available for the treatment of ...

Review the side-effects of Degarelix as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Degarelix approved for advanced prostate cancer Degarelix (injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, from Ferring Pharmaceuticals) has been approved by the FDA for ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...